Navigation Links
ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe

SALT LAKE CITY, Feb. 27 /PRNewswire/ -- ZARS Pharma, Inc. announced today that Rapydan(R) (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorization in Sweden, the United Kingdom, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure. ZARS Pharma has licensed the European sales and marketing rights of Rapydan to EUSA Pharma, Inc. Rapydan received marketing authorization in Sweden in January 2007 and was launched in May 2007. EUSA Pharma began launching Rapydan in other European Union countries in early 2008.

Rapydan is a topical local anesthetic patch approved for use on normal and intact skin to provide surface anesthesia of the skin in connection with needle punctures, in children from 3 years and above, and needle punctures and superficial surgical procedures in adults. Rapydan resembles a small adhesive bandage in appearance and is similar in its ease of application. The patch is applied to the skin for 30 minutes before painful medical procedures. Rapydan is the first product approved in Europe using the patented Controlled Heat-Assisted Drug Delivery or CHADD(R) technology developed by ZARS Pharma.

Rapydan is marketed as Synera(R) (lidocaine 70 mg and tetracaine 70 mg) in the United States and was approved by the U.S. Food and Drug Administration in 2005.

Robert Lippert, President and Chief Executive of ZARS Pharma stated, "We are pleased to announce the approval of Rapydan in a number of European Union countries with a uniquely positioned commercial partner. Rapydan is the first anesthetic patch innovation to be approved in over a decade that works faster than the current standard of care and will soon become a best-in-class therapy for patients undergoing painful needle procedures."

About Rapydan

Rapydan is comprised of a thin layer of a patented local anesthetic formulation integrated with an oxygen-activated heating component (Controlled Heat-Assisted Drug Delivery system). When removed from the storage pouch, Rapydan begins to heat, warming the skin upon application. The heating component is intended to enhance the delivery of the local anesthetics into the skin and to provide vasodilation.

In clinical trials, the most common side effect was local skin reactions, such as erythema, edema, and blanching. Rapydan should not be used for a longer duration than recommended, and is contraindicated in patients with a known history of sensitivity to lidocaine, tetracaine or local anesthetics of the amide or ester type.

About ZARS Pharma

ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using proprietary drug delivery technologies, primarily in the area of pain management and dermatology. ZARS Pharma has developed a rich portfolio of proprietary products and product candidates based on the CHADD technology and on cream technologies (Peel and DuraPeel(TM)) that transform, or phase-change, from an initial liquid phase to a solid phase during application. ZARS Pharma's product portfolio includes two products that have been approved for marketing (Pliaglis(TM) and Synera, latter marketed as Rapydan in Europe). ZARS Pharma currently has one product in a late-stage clinical trial that commenced in June 2007 (ThermoProfen(TM)) and four additional products that have entered various stages of clinical development. For more information on ZARS Pharma, please visit

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on inlicensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has six products on the market, including the antibiotic surgical implant Collatamp(R) G, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, and Rapydan(R), a rapid-onset anesthetic patch. EUSA also has several products in late-stage development, notably Collatamp(R) G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx(R) bupivacaine implant for local post-surgical pain control. For more information, please visit

SOURCE ZARS Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
(Date:11/24/2015)... Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ... Laurin , President and Chief Executive Officer of ProMetic, will ... 27 th Annual Healthcare Conference to be held at ... st , at 8.50am (ET) and ProMetic,s management ... The presentation will be available live via a webcast accessible ...
(Date:11/24/2015)... Va. , Nov. 24, 2015 ... focused on discovering drugs for metabolic disorders, announced ... to its Board of Directors (BOD). Mr. ... officer of Human Genome Sciences (HGS), and also ... Organization. Jim Powers , Chairman and ...
(Date:11/24/2015)... and NEW YORK , November 24, ... investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will work ... immuno-oncology and other areas of unmet medical need. The collaboration ... LSP 5, the latest LSP fund. This is the first ...
(Date:11/24/2015)... -- According to two new studies, fewer men are having ... many doctors, scientists, and public health experts have been pushing ... tests being done, will there be more men dying of ... "Despite the efforts made in regards to early detection ... cause of death in men, killing approximately 27,500 men this ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
Breaking Biology News(10 mins):